These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21742554)

  • 1. Evolution of platinum resistance in high-grade serous ovarian cancer.
    Cooke SL; Brenton JD
    Lancet Oncol; 2011 Nov; 12(12):1169-74. PubMed ID: 21742554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
    Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
    Ng CK; Cooke SL; Howe K; Newman S; Xian J; Temple J; Batty EM; Pole JC; Langdon SP; Edwards PA; Brenton JD
    J Pathol; 2012 Apr; 226(5):703-12. PubMed ID: 22183581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.
    Stronach EA; Cunnea P; Turner C; Guney T; Aiyappa R; Jeyapalan S; de Sousa CH; Browne A; Magdy N; Studd JB; Sriraksa R; Gabra H; El-Bahrawy M
    Oncotarget; 2015 Oct; 6(31):31593-603. PubMed ID: 26267317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
    Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
    Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer.
    Pylväs-Eerola M; Liakka A; Puistola U; Koivunen J; Karihtala P
    Anticancer Res; 2016 Jul; 36(7):3425-31. PubMed ID: 27354603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
    Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
    Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
    Dahm-Kähler P; Borgfeldt C; Holmberg E; Staf C; Falconer H; Bjurberg M; Kjölhede P; Rosenberg P; Stålberg K; Högberg T; Åvall-Lundqvist E
    Gynecol Oncol; 2017 Jan; 144(1):167-173. PubMed ID: 27817932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
    Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
    BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.
    Fotopoulou C; Vergote I; Mainwaring P; Bidzinski M; Vermorken JB; Ghamande SA; Harnett P; Del Prete SA; Green JA; Spaczynski M; Blagden S; Gore M; Ledermann J; Kaye S; Gabra H
    Ann Oncol; 2014 Jan; 25(1):160-5. PubMed ID: 24318743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.